Finance Watch: FibroGen, Amarin And Others Downsize To Survive
9 Meters’ Execs Resign After Bankruptcy, De-Listing
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
